MERLIN explores exciting new opportunities in stromal cell therapy R&D, while making important contributions to the treatment of currently intractable inflammatory and immune mediated liver diseases.
REDDSTAR is an EU funded project which will develop and test stromal cell therapy to treat for diabetes mellitus. The objective is to control blood glucose while also addressing a range of diabetic complications. NEPHSTROM partners Orbsen Therapeutics and Pintail also collaborate on REDDSTAR.
STELLAR is an FP7-funded project interested in developing an alternative to renal replacement therapy making use of newly discovered kidney mesenchymal stem cells.
The SCIENCE project will conduct a multicentre, double-blind placebo-controlled trial with allogeneic adipose-derived stromal cells (CSCC_ASCs) to improve myocardial function in patients with ischemic heart disease and heart failure. In addition, SCIENCE will establish a manufacturing facility for centralised production of allogeneic CSCC_ASCs, and financial health care data to demonstrate the impact of implementing treatment with the proposed new CSCC_ASC product. The project will evaluate advanced existing and new imaging techniques in order to more precisely guide the delivery of stem cells.
VISICORT is a multidisciplinary EU project which will study adverse immune responses to corneal transplantation to pioneer new understandings of immune responses to tissue transplants and implants and develop novel biomarker-based surveillance strategies. VISICORT will also carry out the design and initiation of an optimised clinical trial strategy of immunomodulatory stromal stem cell therapy in high-risk human CT recipients.
RESPINE will develop a rigorously proven, effective treatment of degenerative disc disease (DDD). Via a multicentre, randomized, controlled, phase 2b clinical trial including 112 patients with DDD, RESPINE will assess the efficacy of an allogenic intervertebral mesenchymal stem cell (MSC)-based therapy. The consortium aims to provide new knowledge on immune response & safety associated with allogeneic BM-MSC intradiscal injection. This simple procedure will be cost-effective, and minimally invasive.